# CERENE cryotherapy device by Channel Medsystems

> Channel Medsystems makes Cerene, a single-use cryotherapy device that freezes the uterine lining during a fixed 2.5-minute treatment for certain premenopausal women with heavy menstrual bleeding who have completed childbearing. Its commercial argument is as much about the room as the result: Cerene was designed for a gynecologist's office with local pain control rather than an operating room and general anesthesia. The company also offers physician training, clinical support and patient education.

- **Founded:** 2009
- **Headquarters:** Berkeley, United States
- **Founders:** Daniel Burnett (Founder)
- **Products:** Cerene Cryotherapy Device, Physician training and clinical support, Patient education and provider finder
- **Notable:** Received FDA premarket approval for Cerene on March 28, 2019., Completed a 242-patient, 11-site pivotal trial with follow-up through 36 months., At 36 months, 89% of followed participants reported no, lighter-than-normal or normal periods, and 85% were satisfied or very satisfied.

## Products & services

- **Cerene Cryotherapy Device** — A sterile, prescription-only, single-use endometrial cryoablation device using nitrous oxide for a fixed 2.5-minute treatment in premenopausal women with benign heavy menstrual bleeding who have completed childbearing.
- **Physician training and clinical support** — Training, procedural support and professional education intended to help gynecology practices adopt Cerene in office and outpatient settings.
- **Patient education and provider finder** — Educational material about heavy menstrual bleeding and a directory connecting prospective patients with Cerene-trained clinicians.

## Achievements

- Received FDA premarket approval for Cerene on March 28, 2019.
- Completed a 242-patient, 11-site pivotal trial with follow-up through 36 months.
- At 36 months, 89% of followed participants reported no, lighter-than-normal or normal periods, and 85% were satisfied or very satisfied.
- Reported more than 5,000 women treated by November 2025.
- Reached $30 million in ongoing Series C financing in August 2026.
- Successfully remediated regulatory records after internal fraud; the FDA accepted the remediation plan and later approved the device.

## Latest updates

- **2025-08** — Nelson Whistance became president and CEO, bringing commercialization experience from Gynesonics and Hologic.
- **2025-10** — Channel appointed Tara Murphy as vice president of marketing and Paul Russo as vice president of sales.
- **2025-11** — The company reported that Cerene had been used to treat more than 5,000 women.
- **2026-04** — Cerene partnered with the Hey Girl! Fund on menstrual education.
- **2026-07** — Channel launched the nationwide Know Your Flow education series on menstruation and perimenopause.
- **2026-08** — The ongoing Series C reached $30 million, led by InnovaHealth Partners, to expand commercialization, training, access and evidence generation.

## Links

- Website: https://www.cerene.com/
- LinkedIn: https://www.linkedin.com/company/channel-medsystems/
- Twitter/X: https://twitter.com/cerenecryo
- YouTube: https://www.youtube.com/@CereneTreatment
- Instagram: https://www.instagram.com/cerene_cryotherapy/
- Facebook: https://facebook.com/CereneTreatment
- TikTok: https://www.tiktok.com/@cerene_cryotherapy

---

Profile page: https://yespress.io/cerene-cryotherapy-device-by-channel-medsystems
Published by YesPress — https://yespress.io
Last updated: 2026-09-28